{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,11]],"date-time":"2026-06-11T05:56:25Z","timestamp":1781157385466,"version":"3.54.1"},"reference-count":27,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","theclinics.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Hematology\/Oncology Clinics of North America"],"published-print":{"date-parts":[[2026,6]]},"DOI":"10.1016\/j.hoc.2026.02.007","type":"journal-article","created":{"date-parts":[[2026,6,11]],"date-time":"2026-06-11T00:05:06Z","timestamp":1781136306000},"page":"321-330","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Advances in Neuroblastoma and Wilms Tumor"],"prefix":"10.1016","volume":"40","author":[{"given":"Elizabeth","family":"Sokol","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amy L.","family":"Walz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"27","key":"10.1016\/j.hoc.2026.02.007_bib1","doi-asserted-by":"crossref","first-page":"6459","DOI":"10.1200\/JCO.2005.05.571","article-title":"Evidence for an age cutoff greater than 365 days for neuroblastoma risk group stratification in the Children\u2019s Oncology Group","volume":"23","author":"London","year":"2005","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.hoc.2026.02.007_bib2","series-title":"SEER Cancer Stastitics review 1975-2017","year":"2020"},{"issue":"2","key":"10.1016\/j.hoc.2026.02.007_bib3","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1200\/JCO.2008.16.6876","article-title":"The International Neuroblastoma Risk Group (INRG) staging system: an INRG Task Force report","volume":"27","author":"Monclair","year":"2009","journal-title":"J Clin Oncol"},{"issue":"12","key":"10.1016\/j.hoc.2026.02.007_bib4","doi-asserted-by":"crossref","first-page":"1874","DOI":"10.1200\/JCO.1988.6.12.1874","article-title":"International criteria for diagnosis, staging, and response to treatment in patients with neuroblastoma","volume":"6","author":"Brodeur","year":"1988","journal-title":"J Clin Oncol"},{"issue":"2","key":"10.1016\/j.hoc.2026.02.007_bib5","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1200\/JCO.2008.16.6785","article-title":"The International Neuroblastoma Risk Group (INRG) classification system: an INRG Task Force report","volume":"27","author":"Cohn","year":"2009","journal-title":"J Clin Oncol"},{"issue":"2","key":"10.1016\/j.hoc.2026.02.007_bib6","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1002\/(SICI)1097-0142(19990715)86:2<349::AID-CNCR20>3.0.CO;2-Y","article-title":"Terminology and morphologic criteria of neuroblastic tumors: recommendations by the International Neuroblastoma Pathology Committee","volume":"86","author":"Shimada","year":"1999","journal-title":"Cancer"},{"issue":"10","key":"10.1016\/j.hoc.2026.02.007_bib7","doi-asserted-by":"crossref","first-page":"a014415","DOI":"10.1101\/cshperspect.a014415","article-title":"Neuroblastoma and MYCN","volume":"3","author":"Huang","year":"2013","journal-title":"Cold Spring Harbor Perspect Med"},{"issue":"4","key":"10.1016\/j.hoc.2026.02.007_bib8","doi-asserted-by":"crossref","first-page":"772","DOI":"10.1002\/1097-0142(19880815)62:4<772::AID-CNCR2820620422>3.0.CO;2-U","article-title":"Prognostic factors in neuroblastoma. Clinical, histopathologic, and immunohistochemical features and DNA ploidy in relation to prognosis","volume":"62","author":"Oppedal","year":"1988","journal-title":"Cancer"},{"issue":"12","key":"10.1016\/j.hoc.2026.02.007_bib9","doi-asserted-by":"crossref","first-page":"1940","DOI":"10.1038\/bjc.2011.472","article-title":"Segmental chromosomal alterations lead to a higher risk of relapse in infants with MYCN-non-amplified localised unresectable\/disseminated neuroblastoma (a SIOPEN collaborative study)","volume":"105","author":"Schleiermacher","year":"2011","journal-title":"Br J Cancer"},{"issue":"2","key":"10.1016\/j.hoc.2026.02.007_bib10","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1038\/sj.bjc.6603820","article-title":"Chromosomal CGH identifies patients with a higher risk of relapse in neuroblastoma without MYCN amplification","volume":"97","author":"Schleiermacher","year":"2007","journal-title":"Br J Cancer"},{"issue":"4","key":"10.1016\/j.hoc.2026.02.007_bib11","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1097\/SLA.0b013e31826cbbbd","article-title":"A prospective study of expectant observation as primary therapy for neuroblastoma in young infants: a Children\u2019s Oncology Group study","volume":"256","author":"Nuchtern","year":"2012","journal-title":"Ann Surg"},{"issue":"34","key":"10.1016\/j.hoc.2026.02.007_bib12","doi-asserted-by":"crossref","first-page":"3243","DOI":"10.1200\/JCO.19.00919","article-title":"Maintaining Outstanding Outcomes Using Response- and Biology-Based Therapy for Intermediate-Risk Neuroblastoma: A Report From the Children\u2019s Oncology Group Study ANBL0531","volume":"37","author":"Twist","year":"2019","journal-title":"J Clin Oncol"},{"issue":"21","key":"10.1016\/j.hoc.2026.02.007_bib13","doi-asserted-by":"crossref","first-page":"2243","DOI":"10.1056\/NEJMoa052399","article-title":"Chromosome 1p and 11q deletions and outcome in neuroblastoma","volume":"353","author":"Attiyeh","year":"2005","journal-title":"N Engl J Med"},{"issue":"5","key":"10.1016\/j.hoc.2026.02.007_bib14","doi-asserted-by":"crossref","first-page":"682","DOI":"10.1016\/j.ccell.2014.09.019","article-title":"ALK mutations confer differential oncogenic activation and sensitivity to ALK inhibition therapy in neuroblastoma","volume":"26","author":"Bresler","year":"2014","journal-title":"Cancer cell"},{"issue":"4","key":"10.1016\/j.hoc.2026.02.007_bib15","doi-asserted-by":"crossref","DOI":"10.3390\/cancers10040113","article-title":"ALK in Neuroblastoma: Biological and Therapeutic Implications","volume":"10","author":"Trigg","year":"2018","journal-title":"Cancers"},{"issue":"Suppl 1","key":"10.1016\/j.hoc.2026.02.007_bib16","doi-asserted-by":"crossref","first-page":"S35","DOI":"10.1016\/j.nucmedbio.2008.05.002","article-title":"Radiolabeled metaiodobenzylguanidine for the treatment of neuroblastoma","volume":"35","author":"DuBois","year":"2008","journal-title":"Nucl Med Biol"},{"issue":"4","key":"10.1016\/j.hoc.2026.02.007_bib17","doi-asserted-by":"crossref","first-page":"500","DOI":"10.1016\/S1470-2045(17)30070-0","article-title":"Busulfan and melphalan versus carboplatin, etoposide, and melphalan as high-dose chemotherapy for high-risk neuroblastoma (HR-NBL1\/SIOPEN): an international, randomised, multi-arm, open-label, phase 3 trial","volume":"18","author":"Ladenstein","year":"2017","journal-title":"Lancet Oncol"},{"issue":"8","key":"10.1016\/j.hoc.2026.02.007_bib18","doi-asserted-by":"crossref","first-page":"746","DOI":"10.1001\/jama.2019.11642","article-title":"Effect of Tandem Autologous Stem Cell Transplant vs Single Transplant on Event-Free Survival in Patients With High-Risk Neuroblastoma: A Randomized Clinical Trial","volume":"322","author":"Park","year":"2019","journal-title":"JAMA"},{"issue":"9","key":"10.1016\/j.hoc.2026.02.007_bib19","first-page":"2331","article-title":"Loss of heterozygosity for chromosomes 16q and 1p in Wilms\u2019 tumors predicts an adverse outcome","volume":"54","author":"Grundy","year":"1994","journal-title":"Cancer Res"},{"issue":"29","key":"10.1016\/j.hoc.2026.02.007_bib20","doi-asserted-by":"crossref","first-page":"7312","DOI":"10.1200\/JCO.2005.01.2799","article-title":"Loss of heterozygosity for chromosomes 1p and 16q is an adverse prognostic factor in favorable-histology Wilms tumor: a report from the National Wilms Tumor Study Group","volume":"23","author":"Grundy","year":"2005","journal-title":"J Clin Oncol"},{"issue":"30","key":"10.1016\/j.hoc.2026.02.007_bib21","doi-asserted-by":"crossref","first-page":"2769","DOI":"10.1200\/JCO.18.01972","article-title":"Augmentation of Therapy for Combined Loss of Heterozygosity 1p and 16q in Favorable Histology Wilms Tumor: A Children\u2019s Oncology Group AREN0532 and AREN0533 Study Report","volume":"37","author":"Dix","year":"2019","journal-title":"J Clin Oncol"},{"issue":"6","key":"10.1016\/j.hoc.2026.02.007_bib22","doi-asserted-by":"crossref","first-page":"698","DOI":"10.1200\/JCO.2010.31.5192","article-title":"WT1 mutation and 11P15 loss of heterozygosity predict relapse in very low-risk wilms tumors treated with surgery alone: a children\u2019s oncology group study","volume":"29","author":"Perlman","year":"2011","journal-title":"J Clin Oncol"},{"issue":"4","key":"10.1016\/j.hoc.2026.02.007_bib23","doi-asserted-by":"crossref","first-page":"835","DOI":"10.1097\/SLA.0000000000001716","article-title":"Clinical outcome and biological predictors of relapse after nephrectomy only for very low-risk wilms tumor: a report from Children\u2019s Oncology Group AREN0532","volume":"265","author":"Fernandez","year":"2017","journal-title":"Ann Surg"},{"issue":"26","key":"10.1016\/j.hoc.2026.02.007_bib24","doi-asserted-by":"crossref","first-page":"3189","DOI":"10.1200\/JCO.2015.66.1140","article-title":"Association of Chromosome 1q Gain With Inferior Survival in Favorable-Histology Wilms Tumor: A Report From the Children\u2019s Oncology Group","volume":"34","author":"Gratias","year":"2016","journal-title":"J Clin Oncol"},{"issue":"2","key":"10.1016\/j.hoc.2026.02.007_bib25","doi-asserted-by":"crossref","first-page":"664","DOI":"10.1016\/j.juro.2012.09.115","article-title":"p53 Immunohistochemistry expression in Wilms tumor: a prognostic tool in the detection of tumor aggressiveness","volume":"189","author":"Franken","year":"2013","journal-title":"J Urol"},{"issue":"10","key":"10.1016\/j.hoc.2026.02.007_bib26","doi-asserted-by":"crossref","first-page":"e109924","DOI":"10.1371\/journal.pone.0109924","article-title":"TP53 mutational status is a potential marker for risk stratification in Wilms tumour with diffuse anaplasia","volume":"9","author":"Maschietto","year":"2014","journal-title":"PLoS One"},{"issue":"22","key":"10.1016\/j.hoc.2026.02.007_bib27","doi-asserted-by":"crossref","first-page":"5582","DOI":"10.1158\/1078-0432.CCR-16-0985","article-title":"Significance of TP53 Mutation in Wilms Tumors with Diffuse Anaplasia: A Report from the Children\u2019s Oncology Group","volume":"22","author":"Ooms","year":"2016","journal-title":"Clin Cancer Res"}],"container-title":["Hematology\/Oncology Clinics of North America"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0889858826000080?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0889858826000080?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,6,11]],"date-time":"2026-06-11T04:57:15Z","timestamp":1781153835000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0889858826000080"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6]]},"references-count":27,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026,6]]}},"alternative-id":["S0889858826000080"],"URL":"https:\/\/doi.org\/10.1016\/j.hoc.2026.02.007","relation":{},"ISSN":["0889-8588"],"issn-type":[{"value":"0889-8588","type":"print"}],"subject":[],"published":{"date-parts":[[2026,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Advances in Neuroblastoma and Wilms Tumor","name":"articletitle","label":"Article Title"},{"value":"Hematology\/Oncology Clinics of North America","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.hoc.2026.02.007","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}